Therapeutic polypeptides based on HBV core 18-27 epitope can induce CD8+ CTL-mediated cytotoxicity in HLA-A2+ human PBMCs

Figure 1 Detection of the HBcAg_18-27-specific CD₈⁺ T cells produced with HLA-A*0201/FLPSDFFPSV tetramer-binding assay. A: Non-stimulated HLA-A2⁺ PBMCs from healthy donors; B: Irrelevant peptide pulsed HLA-A2⁺ PBMCs from healthy donors; C: Peptide1 pulsed HLA-A2⁺ PBMCs from healthy donors; D: Peptide2 pulsed HLA-A2⁺ PBMCs from healthy donors; E: Peptide3 pulsed HLA-A2⁺ PBMCs from healthy donors; F: Non-stimulated HLA-A2⁺ PBMCs from chronic hepatitis patients; G: Irrelevant peptide pulsed HLA-A2⁺ PBMCs from chronic hepatitis patients; H: Peptide1 pulsed HLA-A2⁺ PBMCs from chronic hepatitis patients; I: Peptide2 pulsed HLA-A2⁺ PBMCs from chronic hepatitis patients; K: Peptide3 pulsed HLA-A2⁺ PBMCs from chronic hepatitis patients.